Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

Dow Jones

2025/05/30

0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. "We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions," Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 30, 2025 02:32 ET (06:32 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539210008"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539210008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539210008?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539210008","market":"hk","top_or_hot":-1,"title":"Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-30 14:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALC","symbol_name":"Alcon Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2539210008","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539210008","pubTimestamp":1748586720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALC":"Alcon Inc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4198":"医疗保健用品","BK4534":"瑞士信贷持仓"},"translate_title":"爱尔康自上市以来首次获得FDA批准是积极的，但在意料之中——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9},"content_text":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 02:32 ET (06:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}